VP
Insider
Versant Venture Capital VI, L.P.
10% ownerVersant Venture Capital VI, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (0 purchases, 1 sale), most often in Monte Rosa Therapeutics, Inc. (GLUE).
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
–
no filings in the window
Last traded
Sep 18 2025
Filed Sep 22 2025
Median ADV $21.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $17.4M
Shares × price, as filed · by filing month · past 24 months
Most traded names
GLUERecent filings
LENZSALE
LENZ Therapeutics, Inc.
View filing →
$5.7M134,904 sh across 4 lots
Exec Sep 18 2025
Filed Sep 22 2025 · 5:30 PM ET LENZSALE LENZ Therapeutics, Inc. View filing → $10.3M
260,713 sh across 4 lots
Exec Aug 15 2025
Filed Aug 19 2025 · 5:30 PM ET GLUESALE Monte Rosa Therapeutics, Inc. View filing → $1.5M
157,895 sh across 3 lots
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET GLUESALE Monte Rosa Therapeutics, Inc. View filing → $7.4M
1,132,566 sh × $6.53
Exec Sep 20 2024
Filed Sep 24 2024 · 5:30 PM ET